- Company
- Will Uplizna be reimbursed this time?
- by Eo, Yun-Ho Oct 1, 2025 06:11am
- Discussions have resumed regarding the inclusion of the twice-yearly administered new drug ‘Uplizna’ for neuromyelitis optica spectrum disorder (NMOSD) in the national health insurance reimbursement list, which had previously been rejected. According to industry sources, Mitsubishi Tanabe Pharma Korea has resubmitted an application for
- Company
- Will a new market for presbyopia open up?
- by Kim, Jin-Gu Oct 1, 2025 06:10am
- The market for age-related blurry near vision (presbyopia) treatment is emerging as a blue ocean for Korean pharmaceutical and biotech companies. Following a series of new drug approvals by the U.S. Food and Drug Administration (FDA), ophthalmic specialized pharmaceutical companies, including Dae Woo Pharmaceutical, OPTUS Pharma, and Kw
- Company
- ‘COVID-19 vaccination essential for high-risk groups’
- by Son, Hyung Min Oct 1, 2025 06:09am
- The number of hospitalized COVID-19 patients over the past six months has been about threefold that of influenza, underscoring the renewed importance of vaccination, particularly for high-risk groups. Leading experts pointed out that vaccination not only prevents hospitalization and death but also lowers the risk of long COVID, recommendi
- Company
- Ozempic supply begins in Korea…co-promo partner 'undecided'
- by Hwang, byoung woo Sep 30, 2025 06:14am
- As discussions on National Health Insurance reimbursement for Ozempic (semaglutide), a diabetes treatment by Novo Nordisk, accelerate, attention has been garnered to the company's sales and marketing strategy in Korea. Novo Nordisk has stated that the company has not finalized a co-promotion partnership with a domestic company in Korea. Y
- Company
- Three Korean Pharmas avoid Equfina patent
- by Kim, Jin-Gu Sep 30, 2025 06:12am
- Generic companies have succeeded in avoiding the patent of Eisai Korea’s Parkinson’s disease treatment Equfina (safinamide). With early generic launches drawing closer, competition for the first-generic exclusivity among patent challengers is expected to intensify. According to industry sources on the 29th, the Intellectual Property T
- Company
- ‘Need to strengthen access to NMOSD treatments’
- by Son, Hyung Min Sep 30, 2025 06:12am
- On the 25th, Rep. Mi-hwa Seo (Democratic Party of Korea, Health and Welfare Committee) held a policy forum at the National Assembly Hall to strengthen treatment access for neuromyelitis optica spectrum disorder (NMOSD). The forum was co-hosted by Rep. Seo, the Korea NMOSD Patients’ Association, and the Korea Organization for Rare Diseases.
- Company
- Global stage features changes in drugs for metabolic disease
- by Son, Hyung Min Sep 29, 2025 06:08am
- A promotional competition between Korean and international pharmaceutical companies, highlighting the latest treatments for diabetes and metabolic disorders, unraveled at a recent medical conference in Korea. The International Congress of Diabetes and Metabolism (ICDM 2025), held at the Grand Walkerhill Hotel in Seoul over three days st
- Company
- CKD and Kwang Dong win Tagrisso formulation patent suit
- by Kim, Jin-Gu Sep 26, 2025 06:14am
- Generic drugmakers challenging AstraZeneca's patent for the non-small cell lung cancer treatment ‘Tagrisso (osimertinib)’ have won their case in the first instance. According to industry sources on the 25th, the Intellectual Property Trial and Appeal Board (IPTAB) on the 24th ruled in favor of Chong Kun Dang and Kwang Donng Pharmaceutica
- Company
- Teva-Handok challenges mkt with LAI risperidon, Uzedy
- by Hwang, byoung woo Sep 26, 2025 06:12am
- As the schizophrenia treatment paradigm shifts toward managing medication adherence, Teva-Handok has introduced Uzedy (risperidone), a long-acting subcutaneous containing risperidone, to the Korean market. Uzedy is expected to become a new treatment option, enhancing patient convenience with its 1-month and 2-month dosing options and a desig
- Company
- Twice-yearly 'lenacapavir' for HIV expected to land in KOR
- by Eo, Yun-Ho Sep 25, 2025 06:12am
- 'Lenacapavir,' a HIV prevention drug taken twice a year, is expected to be marketed in Korea. According to industry sources, the Ministry of Food and Drug Safety (MFDS) is currently reviewing the approval of lenacapavir from Gilead Sciences Korea. The drug was designated as an orphan drug in January. Its specific indication is "a com
